Umeclidinium/Vilanterol: first global approval.

Article Details

Citation
Copy to clipboard

Scott LJ, Hair P

Umeclidinium/Vilanterol: first global approval.

Drugs. 2014 Mar;74(3):389-95. doi: 10.1007/s40265-014-0186-8.

PubMed ID
24532124 [ View in PubMed
]
Abstract

Umeclidinium/vilanterol (Anoro Ellipta [USA; Canada; proposed Japan]; Anoro [proposed EU]), an inhaled fixed-dose combination of a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, is indicated for once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium/vilanterol received its first global approval in this indication in the USA and has subsequently been approved for use in the same indication in Canada, with submissions for regulatory approval in patients with COPD under review elsewhere, including in Europe and Japan. This article summarizes the milestones in the development of umeclidinium/vilanterol leading to its first approval for maintenance treatment of airflow obstruction in patients with COPD.

DrugBank Data that Cites this Article

Drugs